CBG

Property	Information
Drug Name	Cannabigerol (CBG)
FDA Approval	No (CBG is a cannabinoid compound under investigation; not FDA-approved for any condition)
Used for	Investigational use in cancer research for potential anti-tumor effects
Clinical Trial Phase	Preclinical studies and early research
Clinical Trial Explanation	Not specified
Common Side Effects	Not specifically documented; cannabinoids are generally considered to have a favorable safety profile, but specific studies on CBG's side effects are limited
OS without	Not specified
OS with	Not applicable; research is still in preclinical stages, focusing on cellular and animal models
PFS without	Not specified
PFS with	Not applicable; ongoing studies aim to determine the potential impacts on tumor progression
Usefulness Rating	3
Usefulness Explanation	Not specified
Toxicity Level	2
Toxicity Explanation	Cannabigerol (CBG) is generally considered safe, as it's a non-psychoactive compound found in the cannabis plant. However, specific studies on CBG’s side effects are limited owing to the fact that it is in the early stages of research. Therefore, a rating of 2 is given, indicating a low level of potential toxicity. However, definitive conclusions about its toxicity can only be made after detailed human clinical trials have been conducted.

Notes: Cannabigerol (CBG), a non-psychoactive cannabinoid found in the cannabis plant, has garnered attention in preclinical studies for its potential anti-cancer properties. Research has explored CBG's effects on various cancer cell lines, including its ability to induce apoptosis, inhibit cell proliferation, and potentially target cancer stem cells. While findings are promising, indicating CBG could influence pathways involved in cancer progression, conclusive evidence from human clinical trials is awaited to fully establish its efficacy and optimal use in cancer treatment.

From Ben Williams Book: Not specified

Loading comments...